HLX43 for injection is an innovative targeted PD-L1 antibody-drug conjugate (ADC) developed in collaboration between Henlius Biotech Co., Ltd. and Suzhou Yilian Biotechnology Co., Ltd. This drug is based on a fully humanized IgG1 anti-PD-L1 monoclonal antibody, conjugated with a novel tripeptide linker and a topoisomerase I inhibitor (derived from camptothecin compounds), forming a stable … Read more
Introduction In recent years, two major breakthroughs in cancer treatment—Antibody-Drug Conjugates (ADC) and Bispecific Antibodies (referred to as “bispecifics”)—have demonstrated remarkable efficacy. So, if these two “star drugs” are used in combination, will they produce a stronger anti-cancer effect? Will the toxicity be compounded and difficult to control? A recent clinical study published in the … Read more
This study was led by Professor Guo Jun and Professor Sheng Xi Nan from Peking University Cancer Hospital, and the results have been published in the prestigious international journal The New England Journal of Medicine, and presented at the European Society for Medical Oncology (ESMO) conference. Core Efficacy Data: Significant Extension of Survival This study … Read more
1. Research Background Despite significant efforts by scientists in developing cancer vaccines based on new antigens or mRNA, most research still focuses on the preventive stage. Eliciting substantial anti-tumor immune responses in patients remains a major challenge, primarily due to the weak immunogenicity of cancer vaccines, the immunosuppressive tumor microenvironment, and the low correlation between … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution of traditional drugs into precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution from traditional drugs to precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
Click the arrow to follow us with the “blue text”! 1. 20ins Mutation: The ‘Hard-to-Treat Code’ of the EGFR Family The EGFR exon 20 insertion (20ins) mutation accounts for 4%-12% of NSCLC. Due to the unique mutation site, traditional EGFR-TKIs (such as gefitinib and osimertinib) struggle to bind effectively, leading to its classification as a … Read more
WCLC 2025 has numerous topics on ADCs, and in the spirit of learning, I am joining the discussion. Let’s see how ADCs are viewed in the field of lung cancer, a leading area in cancer treatment, and what research directions exist for ADCs in this domain.Biomarkers for ADCs: IHC and Beyond, presented by Dr. Sewanti … Read more
Currently, the treatment of malignant tumors is a significant focus of public concern. In recent years, various tumor treatment methods, including surgical resection, chemotherapy, radiotherapy, and photodynamic therapy (PDT), have gained widespread attention in the biomedical field. Among these, PDT kills tumor cells by generating reactive oxygen species (ROS) through the light activation of photosensitizers … Read more
Extracellular vesicles (EVs) are nanometer-sized particles enveloped by phospholipids that are secreted by cells into the surrounding environment. EVs can convey various biomolecules that mediate intercellular communication and play crucial roles in physiological and pathological processes. Therefore, EVs are emerging as new biomarkers, therapeutic targets, and drug delivery vehicles for various diseases. However, the isolation … Read more